Fuller Research Foundation Clinical Trials is a grant from Fuller Research Foundation that funds rigorous clinical research into environmental and lifestyle interventions for au.

Fuller Research Foundation — Clinical Research in Lifestyle Intervention 501(c)(3) Nonprofit Organization Advancing the Science of Lifestyle Intervention The Fuller Research Foundation funds rigorous clinical research into environmental and lifestyle interventions for autoimmune conditions, metabolic disease, and mental illness.

Bridging Anecdote and Evidence We fund high-quality, ethically conducted research to evaluate interventions that have shown remarkable promise but lack the rigorous clinical evidence needed to reach mainstream medicine. Eligible applicants include Nonprofit organizations conducting clinical trials in these fields. Award amount: Varies.

Fuller Research Foundation — Clinical Research in Lifestyle Intervention 501(c)(3) Nonprofit Organization Advancing the Science of Lifestyle Intervention The Fuller Research Foundation funds rigorous clinical research into environmental and lifestyle interventions for autoimmune conditions, metabolic disease, and mental illness.

Bridging Anecdote and Evidence We fund high-quality, ethically conducted research to evaluate interventions that have shown remarkable promise but lack the rigorous clinical evidence needed to reach mainstream medicine.

We fund and support rigorous, IRB-approved randomized controlled trials—the gold standard of clinical evidence—evaluating ketogenic and carnivore dietary interventions for inflammatory, autoimmune, and psychiatric conditions. We curate the growing body of published research on ketogenic and carnivore diets across mental illness, autoimmunity, and metabolic disease—making the science accessible to clinicians, patients, and policymakers.

We track and share credible news coverage from leading institutions—Stanford Medicine, UCSF, NPR, and others—to keep the public and medical community informed of developments in this rapidly evolving field. Thousands of patients report life-changing remission through ketogenic and carnivore dietary approaches.

Yet the formal clinical evidence—the kind that changes medical guidelines and informs prescribing—is severely underfunded and underproduced. The urgency is compounded by a growing body of research documenting the long-term neurological and psychological consequences of psychiatric medications — including antidepressants and benzodiazepines.

If ketogenic dietary therapy proves effective as a treatment for the conditions these drugs are prescribed for, it offers not only a path to recovery but a way to avoid the iatrogenic harm that so often follows long-term pharmaceutical use. Getting people effective alternatives sooner matters.

Without rigorous RCTs, these interventions cannot be recommended by physicians, reimbursed by insurers, or approved by ethics boards for wider study. The Fuller Research Foundation exists to close that gap. Americans with Autoimmune Disease Yet nearly zero large-scale RCTs examine dietary intervention as treatment for IBD or RA.

Active Ketogenic Psychiatry Trials Worldwide Interest is surging, but trials remain small, underfunded, and difficult to replicate. Large-Scale RCTs for Carnivore/Lion Diet Despite thousands of documented remissions, no major controlled trial existed before our study. Foundation Leadership & Advisors Our work is guided by credentialed clinicians, researchers, and advocates with firsthand experience in metabolic and dietary medicine.

Our Landmark Clinical Trial Effectiveness and Efficacy of a Ketogenic or Carnivore (Lion) Diet for Quality of Life and Symptom Burden in Individuals with Symptomatic IBD or Rheumatoid Arthritis: A Randomized Controlled Clinical Trial Study Type Randomized Controlled Trial Lead Researcher Dr. Robert Abbott, MD This landmark trial addresses a critical evidence gap—no large-scale RCTs have previously examined ketogenic or carnivore diets for IBD or rheumatoid arthritis.

Participants are followed over six months with regular clinical monitoring, laboratory assessments, and standardized outcome measures. Your Support Funds Research That Changes Lives Every tax-deductible contribution goes directly toward funding researchers, laboratory work, and ethical, IRB-approved studies. Help bridge the gap to evidence-based alternatives.

A Foundation Built on Science, Urgency, and Personal Experience The Fuller Research Foundation is a 501(c)(3) nonprofit organization committed to rigorously advancing scientific knowledge of dietary and alternative interventions for the management of chronic diseases.

The Foundation supports high-quality, ethically conducted research—primarily through funding and collaboration—to evaluate the safety, efficacy, and mechanisms of approaches such as strict ruminant-meat-based ketogenic elimination protocols, broader ketogenic diets, and related evidence-informed nutritional strategies. We aim to empower individuals with effective, sustainable solutions for improving their health and well-being.

Through collaboration with researchers, healthcare providers, and communities, we strive to illuminate pathways to better health, foster informed decision-making, and inspire hope for those facing chronic conditions. The Fuller Research Foundation was established by Mikhaila Fuller, whose path to founding it was anything but straightforward.

Over 21 years, she experienced severe autoimmune disease and treatment-resistant mood disorders before discovering the profound therapeutic potential of ketogenic and carnivore dietary protocols. What followed was not simply recovery — it was a decade of navigating the aftermath of long-term pharmaceutical treatment, including the well-documented but rarely discussed harms of long-term SSRI use and withdrawal.

That experience shaped a broader mission: not only to fund rigorous research into dietary and lifestyle interventions for chronic disease, but to build an honest, evidence-based understanding of the full picture — the environmental causes that drive illness, the dietary and lifestyle approaches that can reverse it, and the pharmaceutical harms that so often remain long after the original diagnosis has been addressed.

The Foundation's research agenda and public education work reflect all three of these dimensions. Much of the current evidence in autoimmunity stems from animal models, where ketogenic diets have demonstrated reductions in inflammation, modulation of immune responses (such as shifting toward anti-inflammatory Treg cells), and symptom amelioration, often linked to ketone bodies like β-hydroxybutyrate.

In humans, small-scale pilot studies have explored ketogenic diets primarily in multiple sclerosis, reporting improvements in fatigue, depression, quality of life, and inflammatory markers with good safety and tolerability over periods like 6 months. Large-scale, definitive randomized controlled trials across broader autoimmune diseases—lupus, Crohn's disease, IBD, or general autoimmunity—are scarce.

High-quality, large-scale human trials are needed to establish efficacy, long-term safety, and mechanisms. The Fuller Research Foundation is dedicated to conducting and supporting research that is transparent, methodologically sound, and participant-centered.

By partnering with qualified investigators, academic institutions, and healthcare professionals, the Foundation seeks to generate reliable evidence on the role of targeted dietary interventions in chronic disease management—contributing meaningfully to the broader scientific community's understanding and supporting informed clinical decision-making.

Founders, Researchers & Advisors The Fuller Research Foundation was built by people who have lived through serious illness and witnessed firsthand what dietary intervention can do. That experience informs everything we fund.

Founder, Fuller Research Foundation Mikhaila Fuller is a health advocate and entrepreneur whose personal recovery from treatment-resistant autoimmune and psychiatric disease—including juvenile rheumatoid arthritis and severe depression—drives her mission to build rigorous scientific evidence for dietary medicine.

In 2017 she developed the Lion Diet, a ruminant-meat-based elimination protocol, and experienced complete remission of symptoms that had defined her life since childhood. Her father, Dr. Jordan B. Peterson, followed the same protocol in 2018 with similar results.

She founded the Fuller Research Foundation to translate that anecdotal evidence into peer-reviewed, IRB-approved science. She also co-founded Peterson Academy and serves as founder of Fuller Health.

Co-Founder, Fuller Research Foundation Jordan Fuller is Co-Founder and COO of the Fuller Research Foundation, overseeing day-to-day operations, strategic partnerships, and the communications infrastructure connecting the Foundation's research mission with donors and the medical community.

Chief of Staff, Fuller Research Foundation Juan Quintero serves as Chief of Staff at the Fuller Research Foundation, overseeing administrative operations and organizational coordination. With extensive experience in chief of staff and administrative leadership roles, he ensures the Foundation runs with the efficiency and accountability that rigorous scientific work demands. Researcher — Data Analytics & AI Ph.

D. Psychology, University of Toronto Victor Swift brings expertise in data analytics, artificial intelligence, and clinical psychology to the Fuller Research Foundation. He holds a Ph.

D. in Psychology from the University of Toronto, where he developed deep expertise in research methodology and statistical analysis. Victor applies his background in AI and data science to strengthen the Foundation's research infrastructure and analytical capabilities.

MD, University of Virginia School of Medicine Functional Medicine — Kresser Institute Functional Medicine — Institute for Functional Medicine Former Director of Research, Ruscio Institute Dr. Robert Abbott is an integrative physician and founder of Resilient Roots: Functional and Evolutionary Medicine in Charlottesville, Virginia.

He holds an MD from the University of Virginia and completed advanced training through the Kresser Institute and the Institute for Functional Medicine. A former clinician and director of research at the Ruscio Institute, his peer-reviewed work includes studies on dietary interventions for depression and Hashimoto's thyroiditis. He serves as lead researcher on the Foundation's current randomized controlled trial.

Dr. Jordan B. Peterson, Ph. D.

Ph. D. Clinical Psychology, McGill University Professor Emeritus, University of Toronto Former Faculty, Harvard University 100+ Peer-Reviewed Publications Dr. Jordan B.

Peterson is a clinical psychologist, Professor Emeritus at the University of Toronto, and bestselling author of 12 Rules for Life and Beyond Order . He holds a Ph. D.

from McGill University, conducted post-doctoral research there, and taught at Harvard before two decades at the University of Toronto—publishing over 100 peer-reviewed papers with students and colleagues.

Effectiveness and Efficacy of a Ketogenic or Carnivore (Lion) Diet for Quality of Life and Symptom Burden in Individuals with Symptomatic Inflammatory Bowel Disease or Rheumatoid Arthritis: A Randomized Controlled Clinical Trial Study Type Randomized Controlled Trial Lead Researcher Dr. Robert Abbott, MD Conditions IBD & Rheumatoid Arthritis This study is a randomized controlled clinical trial evaluating whether two therapeutic dietary approaches—a ketogenic diet and a carnivore (Lion) diet—can improve quality of life, reduce symptoms, and influence measures of disease activity in adults with inflammatory bowel disease (IBD) or rheumatoid arthritis (RA).

It is the largest study of its kind ever conducted on these dietary approaches for autoimmune and inflammatory conditions. Despite increasing interest in dietary interventions for chronic inflammatory conditions, there remains a significant evidence gap.

The most substantial published data to date is a 2024 case series of 10 patients with IBD, all of whom achieved clinical remission using carnivore-ketogenic diets—but that study was small, uncontrolled, and observational. This trial provides the rigorous, peer-reviewable evidence needed to inform future clinical guidelines and treatment options for patients with these debilitating conditions.

The trial enrolls 160 adults aged 18–64 with a confirmed diagnosis of IBD (Crohn's disease or ulcerative colitis) or rheumatoid arthritis. Participants are randomly assigned to one of three groups: Group 1 — Ketogenic Diet: A high-fat, very low-carbohydrate dietary protocol maintained for 3 months of active intervention.

Group 2 — Carnivore (Lion) Diet: A ruminant meat-based elimination protocol (beef, salt, water) maintained for 3 months of active intervention. Group 3 — Control: Participants continue their current diet and are monitored for 3 months, providing a contemporaneous comparator. All participants complete a 3-month baseline monitoring period before beginning their assigned intervention.

Participants are followed over the full 6-month period with regular clinical monitoring, laboratory assessments, and standardized outcome measures to ensure scientific rigor and participant safety.

All aspects of the trial—including recruitment, consent processes, data collection, and monitoring—are conducted in strict compliance with IRB approval, federal regulations, and ethical guidelines to prioritize participant welfare and data integrity.

Primary & Secondary Outcomes The primary goal of this study is to determine whether ketogenic or carnivore dietary therapy improves: Health-related quality of life (validated disease-specific instruments) Disease-specific symptom burden (IBD: CDAI/Mayo score; RA: DAS28) Objective inflammatory markers (CRP, ESR, fecal calprotectin where applicable) Secondary aims include assessing feasibility and adherence, safety (adverse events, nutritional status, cardiometabolic changes including blood lipids and metabolic panels), and whether sustained nutritional ketosis (measured via blood ketone monitoring) correlates with clinical outcomes.

What Participation Involves After completing the eligibility application and being confirmed as a participant, enrolled individuals can expect: Detailed onboarding, dietary guidance, and informed consent process Random assignment to a dietary intervention or control group 6 months following your assigned dietary protocol with full research team support Periodic labs throughout the study Regular check-ins with the research team via telehealth Completion of validated symptom and quality-of-life questionnaires at defined intervals A group participants can join for support Dietary logging and ketone monitoring The study is conducted remotely, so participants across the United States are eligible to enroll.

Lab work is coordinated through partner facilities. There is a one-time $200 enrollment fee to partially cover lab testing. All other laboratory testing, clinical monitoring, administration and ongoing research support throughout the study are fully covered by the Foundation.

Research Ethics & Institutional Oversight IRB Status Approved — Full Board Review Data Protection HIPAA-Compliant Trial Design Randomized Controlled Lead Institution Resilient Roots Functional Medicine Informed Consent Required of All Participants Publication Intent Peer-Reviewed Journal The Fuller Research Foundation is committed to the highest standards of research ethics.

All studies funded or conducted by the Foundation are subject to institutional review board oversight, participant informed consent, and HIPAA-compliant data handling. Conflicts of interest are disclosed in all publications. We publish results whether or not they confirm our hypotheses.

Eligibility & How to Apply You may be eligible to participate if you meet all of the following criteria: Formal medical diagnosis of IBD (Crohn's disease or ulcerative colitis) or rheumatoid arthritis, with documentation No prior experience with ketogenic or carnivore diets Not currently pregnant or breastfeeding Residing in the United States (required for laboratory coordination) Willing to adhere to the assigned dietary protocol for 3–6 months depending on randomization There is a one-time $200 enrollment fee to cover intake processing and administration.

All laboratory testing, monitoring, and clinical assessments throughout the study are fully covered by the Foundation. All prospective participants receive complete information about procedures, potential risks and benefits, and their rights before providing informed consent.

All personal health information collected is handled in accordance with our HIPAA Notice of Privacy Practices, which outlines how protected health information is used, disclosed, and safeguarded. Ketogenic & Carnivore Studies Iatrogenic Injury Studies Mitochondrial Dysfunction A curated collection of peer-reviewed studies Scientific interest in ketogenic diets has expanded rapidly in recent years.

Long established for intractable epilepsy since the 1920s, the field now sees over 600 publications annually on PubMed, driven by clinical trials, meta-analyses, and reviews exploring broader applications. This growth is vital for people with chronic conditions—obesity, type 2 diabetes, autoimmune disorders, and neurological or psychiatric issues—where standard treatments often fall short.

The Fuller Research Foundation is dedicated to supporting transparent, high-quality research to close evidence gaps. Dietary interventions should always be undertaken under medical supervision. Awareness and Best Practices in Using Ketogenic Therapy to Treat Serious Mental Illness: A Modified Delphi Consensus Published in Frontiers in Nutrition.

A modified Delphi method with 47 expert clinicians reached 100% consensus on 33 statements regarding ketogenic metabolic therapy (KMT) for major depressive disorder, bipolar disorder, and schizophrenia. Defines KMT, provides guidance on patient selection, monitoring, supplementation, and contraindications.

Case Report: Remission of Schizophrenia Using a Carnivore Ketogenic Metabolic Therapy Schizophrenia remission achieved through carnivore ketogenic diet with nutritional therapy practitioner support.

The Ketogenic Diet and Metabolic Treatments for Neuropsychiatric Disorders Reviews ketogenic and related metabolic therapies for neuropsychiatric conditions, emphasizing brain metabolism shifts and the therapeutic potential of nutritional ketosis.

Ketogenic Diet as a Therapeutic Intervention for Obsessive-Compulsive Disorder: A Case Series of Three Patients Case series of three patients with OCD achieving symptom improvement or remission via ketogenic diet intervention. Average Y-BOCS scores reduced by 21 points (90. 5% mean decrease); all three achieved medication-free remission.

Ketogenic Diets for Body Weight Loss: A Comparison with Other Diets Compares ketogenic diets to other approaches for weight loss, highlighting efficacy, adherence, and metabolic effects.

A Pilot Study of a Ketogenic Diet in Bipolar Disorder: Clinical, Metabolic and Magnetic Resonance Spectroscopy Findings Examines ketogenic diet effects in bipolar disorder, including clinical symptom changes, metabolic outcomes, and brain spectroscopy data.

Ketogenic Diet Suppresses Colorectal Cancer through the Gut Microbiome Long Chain Fatty Acid Stearate Research showing that ketogenic diets may suppress colorectal cancer progression via gut microbiome-mediated effects involving stearate, a long-chain fatty acid. Published in Nature Communications.

Clinical Research Framework Proposal for Ketogenic Metabolic Therapy in Glioblastoma Proposes a framework for clinical research on ketogenic metabolic therapy as a treatment for glioblastoma (brain cancer), focusing on metabolic vulnerabilities of tumor cells.

Carnivore–Ketogenic Diet for the Treatment of Inflammatory Bowel Disease: A Case Series of 10 Patients Ten patients with IBD (6 ulcerative colitis, 4 Crohn's disease) achieved remission or major symptom improvement using ketogenic carnivore-style diets. Patients reported high satisfaction and potential biological mechanisms supporting this approach for IBD management.

The Effects of Ketogenic Metabolic Therapy on Mental Health and Metabolic Outcomes in Schizophrenia and Bipolar Disorder: A Randomized Controlled Clinical Trial Protocol Protocol for a randomized placebo-controlled trial involving 100 patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Tests a 14-week dietitian-supervised modified ketogenic diet versus standard healthy eating control.

Complete Remission of Depression and Anxiety Using a Ketogenic Diet: Case Series Three adults with major depression and generalized anxiety disorder treated with personalized animal-based ketogenic metabolic therapy. All achieved complete remission within 7–12 weeks, alongside weight loss (10. 9–14.

8%) and metabolic improvements. Animal-based Ketogenic Diet Puts Severe Anorexia Nervosa into Multi-Year Remission: A Case Series Three patients with severe, treatment-refractory anorexia nervosa (BMI nadirs as low as 10. 7 kg/m²) achieved sustained remission (1–5 years).

Weight gain >20 kg each, reduced anxiety, and improved mental well-being. First reported use of a unimodal ketogenic intervention for anorexia. Case Report: Ketogenic Diet Acutely Improves Cognitive Function in Patient with Down Syndrome and Alzheimer's Disease Acute cognitive improvements in a patient with Down syndrome and Alzheimer's disease following ketogenic diet implementation, suggesting neuroprotective effects via ketosis.

All-Meat Ketogenic Diet for Long-Term Management of Candida Vulvovaginitis and Vaginal Hidradenitis Suppurativa: 47-Month Follow-Up Long-term case report of a patient successfully managing recurrent Candida vulvovaginitis and vaginal hidradenitis suppurativa with an all-meat ketogenic diet.

Behavioral Characteristics and Self-Reported Health Status among 2029 Adults Consuming a "Carnivore Diet" Large survey of 2029 adults following a carnivore diet for a median of 14 months. 95% reported improvements in overall health; few adverse effects; BMI reduction and benefits for diabetes.

Ketogenic Diet as a Metabolic Treatment for Mental Illness Examines how ketosis may address underlying brain energy deficits in conditions like schizophrenia, bipolar, and depression. Ketogenic Therapy in Serious Mental Illness: Emerging Evidence Overview of growing evidence supporting ketogenic metabolic therapy for serious mental illnesses including schizophrenia and bipolar disorder.

Ketogenic Diet for Schizophrenia: Clinical Implication Summarizes case studies, mechanisms (ketone bodies as alternative brain fuel), and potential for symptom reduction in schizophrenia. The Ketogenic Diet and Remission of Psychotic Symptoms in Schizophrenia: Two Case Studies Two case studies demonstrating remission of psychotic symptoms in schizophrenia patients using ketogenic diets.

Ketogenic Diet as a Metabolic Therapy for Mood Disorders: Evidence and Developments Reviews mechanisms (metabolic shifts, reduced inflammation) and preliminary evidence showing benefits for depression and bipolar symptoms.

The Effects of the Ketogenic Diet on Psychiatric Symptomatology, Weight and Metabolic Dysfunction in Schizophrenia Patients Investigates ketogenic diet impacts on psychiatric symptoms, weight, and metabolic issues in schizophrenia, reporting improvements across all areas.

Complete Cessation of Recurrent Cervical Intraepithelial Neoplasia (CIN) by the Paleolithic Ketogenic Diet: A Case Report Patient with recurrent high-grade CIN achieved complete cessation after adopting a paleolithic ketogenic diet. Follow-up Pap smears normalized within months; sustained normal results over 26 months.

Ketogenic Diet in the Treatment of Schizoaffective Disorder: Two Case Studies Two case studies showing benefits of ketogenic diets for symptom management in schizoaffective disorder. Diets and Disorders: Can Foods or Fasting Be Considered Psychopharmacologic Therapies? Discussion on whether dietary interventions including ketogenic diets or fasting can function as psychopharmacologic treatments for psychiatric disorders.

The Neuroprotective Properties of Calorie Restriction, the Ketogenic Diet, and Ketone Bodies Maalouf, Rho & Mattson. Brain Research Reviews. Comprehensive review demonstrating how ketone bodies protect neurons by improving mitochondrial function, reducing oxidative damage, and modulating apoptotic pathways — establishing the metabolic basis for ketogenic neuroprotection across neurological and psychiatric conditions.

Help Fund the Next Wave of Studies Most nutritional studies in these areas remain small or underfunded. Your support helps accelerate the rigorous trials that could validate these approaches for doctors, patients, and policymakers worldwide.

Iatrogenic Injury Research SSRIs, SNRIs, and benzodiazepines are among the most widely prescribed drugs in the world, yet harms associated with their use and discontinuation remain systematically underreported and poorly communicated to patients.

Akathisia — a drug-induced state of profound inner restlessness and psychological torment — is one of the most serious: routinely misidentified as worsening mental illness, it has been directly linked to suicidal ideation, self-harm, and violence, and can persist for months or years after stopping.

Benzodiazepine dependence can develop in days — far shorter than the 2–4 weeks guidelines typically cite — and withdrawal can be severe and protracted, causing neurological symptoms, cognitive impairment, and autonomic dysfunction lasting years. This has been documented since the 1980s and remains inadequately addressed in prescribing practice. For more information visit prescribed-harm.

com (coming soon). Long-Term Neurological Consequences Following Benzodiazepine Exposure: A Scoping Review Shade, Ritvo et al. PLoS One.

Comprehensive scoping review documenting the range and persistence of neurological consequences following benzodiazepine use, including cognitive impairment, sensory disturbance, and autonomic dysfunction lasting well beyond discontinuation. Evaluation of Akathisia in Patients Receiving Selective Serotonin Reuptake Inhibitors/Serotonin and Noradrenaline Reuptake Inhibitors Akgoz, Kara et al. Behavioural Pharmacology.

Clinical study directly evaluating the incidence and severity of akathisia in patients prescribed SSRIs and SNRIs, finding the condition is common and frequently unrecognized by treating clinicians. The Serotonin Theory of Depression: A Systematic Umbrella Review of the Evidence Moncrieff et al. Molecular Psychiatry.

Landmark umbrella review finding no consistent evidence that depression is caused by lowered serotonin activity or concentrations — directly undermining the primary scientific rationale used to justify SSRI prescribing for decades. Long-Term Consequences of Benzodiazepine-Induced Neurological Dysfunction: A Survey Ritvo, Foster et al. PLoS One.

Survey of long-term benzodiazepine users documenting persistent neurological dysfunction including cognitive impairment, emotional blunting, sensory symptoms, and autonomic dysregulation — many reporting symptoms lasting years after discontinuation. Experiences with Benzodiazepine Use, Tapering, and Discontinuation: An Internet Survey Finlayson, Macoubrie et al. Therapeutic Advances in Psychopharmacology.

Large patient survey documenting the difficulty of benzodiazepine discontinuation, high rates of protracted withdrawal, and the inadequacy of current clinical guidance — with many patients reporting their prescribers were unaware of or dismissed their withdrawal symptoms. Movement Disorders Induced by Psychiatric Drugs That Do Not Block Dopamine Receptors Friedman JH. Parkinsonism & Related Disorders.

Documents that SSRIs and other non-dopamine-blocking psychiatric drugs can cause movement disorders including akathisia — important because clinicians often assume such effects are limited to antipsychotics, leaving SSRI-induced akathisia unrecognized and untreated. A Systematic Review into the Incidence, Severity and Duration of Antidepressant Withdrawal Effects: Are Guidelines Evidence-Based? Davies & Read.

Addictive Behaviors. Finds that antidepressant withdrawal is common (56% of patients) and often severe (46% of those affected), and that current clinical guidelines significantly understate the problem — often describing withdrawal as mild and brief when evidence suggests otherwise. Suicidality and Aggression During Antidepressant Treatment: Systematic Review and Meta-Analyses Based on Clinical Study Reports Sharma et al.

BMJ. Using unpublished clinical study reports obtained via freedom of information requests, found antidepressants double the risk of suicidality and aggression in adults and children compared to placebo — effects obscured in the published trial literature. Benzodiazepine Use and Risk of Alzheimer's Disease: Case-Control Study Billioti de Gage, Moride et al.

BMJ. Case-control study finding benzodiazepine use was associated with an increased risk of Alzheimer's disease, with longer duration of use associated with greater risk — adding long-term neurodegenerative harm to the established concerns about benzodiazepine prescribing. Antidepressant-Induced Akathisia-Related Homicides Associated with Diminishing Mutations in Metabolizing Genes of the CYP450 Family Lucire & Crotty.

Pharmacogenomics and Personalized Medicine. Forensic study of eight individuals who committed homicide while taking antidepressants, none with prior histories of violence. All had CYP450 polymorphisms causing dangerously elevated drug levels and severe akathisia — establishing the mechanism by which a standard prescription can drive catastrophic violence.

Neuroleptic-Induced Akathisia and Violence: A Review Leong & Silva. Journal of Forensic Sciences. Forensic review documenting that the association between akathisia and violent behavior was not formally recognized until 25 years after antipsychotics were introduced — meaning patients were being driven to violence by their medications while the profession failed to identify the cause.

SSRI-Induced Extrapyramidal Side-Effects and Akathisia: Implications for Treatment Lane RM. Journal of Psychopharmacology. Comprehensive review demonstrating that SSRIs can induce akathisia through serotonergically-mediated inhibition of dopamine pathways.

Documents that unrecognized akathisia leads to dose increases (worsening the condition), misdiagnosis as psychiatric deterioration, and escalating medication burden. Reexposure to Fluoxetine After Serious Suicide Attempts by Three Patients: The Role of Akathisia Rothschild & Locke. Journal of Clinical Psychiatry.

Landmark case series of three patients who made serious suicide attempts during fluoxetine treatment and developed severe akathisia on retreatment. All reported that akathisia — not depression — had precipitated their suicide attempts. Symptoms resolved completely with discontinuation or propranolol, providing direct early evidence that SSRI-induced akathisia can cause suicidality in patients not previously suicidal.

Mitochondrial Dysfunction Research A growing body of evidence suggests that mitochondrial dysfunction — the impaired ability of cells to produce energy — is a shared mechanism underlying many chronic diseases, mental health conditions, and iatrogenic injuries. Mold biotoxins disrupt mitochondrial respiration directly.

Long-term psychiatric medications, including SSRIs and benzodiazepines, have been shown to impair mitochondrial function and may contribute to the neurological symptoms that outlast their use. And the ketogenic diet, by providing ketones as an alternative fuel, may restore cellular energy production where glucose metabolism has been compromised. The studies below span all three dimensions of this connection.

Different Effects of SSRIs, Bupropion, and Trazodone on Mitochondrial Functions and Monoamine Oxidase Isoform Activity Šupták et al. Antioxidants. Demonstrates that SSRIs are the strongest inhibitors of mitochondrial Complex I among common antidepressants — with direct implications for why long-term SSRI use may cause persistent neurological symptoms and energy dysregulation.

Mitochondrial Dysfunction Following Repeated Administration of Alprazolam Causes Attenuation of Hippocampus-Dependent Memory Consolidation in Mice Aging, 2023. The first study to establish a direct causal link between alprazolam (benzodiazepine)-induced mitochondrial dysfunction and cognitive impairment — providing a mechanistic explanation for the memory and neurological symptoms reported by long-term benzodiazepine users.

Mycotoxin-Assisted Mitochondrial Dysfunction and Cytotoxicity: Unexploited Tools Against Proliferative Disorders Islam et al. IUBMB Life. Documents how mycotoxins — including citrinin, aflatoxin, and T-2 toxin produced by mold — cause mitochondrial dysfunction at low doses through oxidative stress and disruption of the electron transport chain, contributing to multi-system illness.

Mitochondrial Dysfunction Induced by Sertraline, an Antidepressant Agent Toxicological Sciences. Shows that sertraline (Zoloft) induces mitochondrial permeability transition, ATP depletion, and inhibition of respiratory complexes — direct mitochondrial toxicity at clinically relevant concentrations. Modulation of Oxidative Stress and Mitochondrial Function by the Ketogenic Diet Milder & Patel.

Epilepsy Research. Reviews how the ketogenic diet reduces oxidative stress and enhances mitochondrial function — including upregulation of antioxidant defenses and improvements in electron transport chain efficiency — with implications well beyond epilepsy. The Neuroprotective Properties of Calorie Restriction, the Ketogenic Diet, and Ketone Bodies Maalouf, Rho & Mattson.

Brain Research Reviews. Comprehensive review demonstrating how ketone bodies protect neurons by improving mitochondrial function, reducing oxidative damage, and modulating apoptotic pathways — establishing the metabolic basis for ketogenic neuroprotection. Mitochondrial Dysfunction and Psychiatric Disorders Rezin et al.

Neurochemical Research. Reviews the evidence for mitochondrial dysfunction as a contributing factor in bipolar disorder, major depression, and schizophrenia — including impaired oxidative phosphorylation and reduced mitochondrial enzyme activity across all three conditions. Mitochondrial Biogenesis in the Anticonvulsant Mechanism of the Ketogenic Diet Bough et al.

Annals of Neurology. Landmark study demonstrating that the ketogenic diet significantly upregulates mitochondrial biogenesis — increasing the number and efficiency of mitochondria in brain cells — as a key mechanism behind its therapeutic effects. A Mitochondrial Paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary Medicine Wallace DC.

Annual Review of Genetics. Highly influential review establishing mitochondrial dysfunction as a central driver of metabolic and degenerative disease — providing the foundational framework for understanding why so many seemingly disparate conditions share common cellular mechanisms. Mitochondrial Dysfunction in Schizophrenia: A Possible Linkage to Dopamine Ben-Shachar D.

Journal of Neurochemistry. Seminal paper establishing the connection between mitochondrial impairment and dopaminergic dysfunction in schizophrenia — suggesting that disrupted cellular energy production may be at the root of symptoms previously attributed solely to neurotransmitter imbalance. Ketone Bodies, Potential Therapeutic Uses Veech et al.

IUBMB Life. Foundational paper by pioneer researcher Richard Veech establishing that ketone bodies are a more efficient fuel for the mitochondria than glucose — producing more ATP per unit of oxygen consumed and reducing oxidative stress in the process.

Keto & Autoimmune Disease UCSF News · November 2024 How the Keto Diet Could One Day Treat Autoimmune Disorders University article on keto boosting anti-inflammatory compounds via gut microbes, reducing MS-like symptoms in models, with potential for human autoimmune conditions. Can the Ketogenic Diet Help with Autoimmune Disease?

Reviews the mechanisms by which ketosis may reduce autoimmune activity — including suppression of the NLRP3 inflammasome, reduction in pro-inflammatory cytokines, and improved gut barrier function. Carnivore Diet & Autoimmunity Can the Carnivore Diet Help Autoimmune Conditions?

Covers patient cases and early clinical evidence suggesting elimination of plant-based compounds may reduce autoimmune flares, with expert commentary on the mechanisms and risks. Diet Doctor · August 2018 Could an All-Meat Diet Cure Some Diseases? Features Mikhaila Peterson's remission from severe juvenile rheumatoid arthritis and other autoimmune issues on an all-meat diet.

Ketogenic Diet & Mental Illness U.S. News & World Report · February 2026 Keto Diet A Potential Treatment For Depression, Trial Shows Reports randomized trial showing antidepressant benefits in treatment-resistant depression, with ketosis stabilizing neurons and reducing brain inflammation.

Stanford Medicine Magazine · September 2025 Diet Has Outsized Role in Preventing and Treating Illness Covers metabolic links to mental illness; notes patients with schizophrenia showing 32% reduction in symptom intensity on keto.

Stanford Medicine · April 2025 Five Things to Know About Keto Therapy and Serious Mental Illness Discusses how ketogenic therapy reduces brain inflammation linked to depression, anxiety, schizophrenia, and bipolar; highlights pilot improvements and ongoing larger trials. Schizophrenia and Food: Do Keto and Gluten-Free Diets Help?

Covers small studies and case reports where keto reduced inflammation and improved schizophrenia symptoms, including long-term remission in one case. Stanford Medicine News · April 2024 Pilot Study Shows Ketogenic Diet Improves Severe Mental Illness Pilot trial of 21 patients with schizophrenia/bipolar: 79% showed clinically meaningful psychiatric improvements, plus significant metabolic gains.

The Guardian · January 2024 How the Ketogenic Diet Could Help Treat Mental Illness Reports on emerging clinical trials testing ketogenic therapy for bipolar disorder and schizophrenia, including Stanford research, with commentary from psychiatrists on the metabolic basis of serious mental illness. Patients Say Keto Helps with Their Mental Illness.

Science Is Racing to Understand Why Patient anecdotes and research on keto alleviating bipolar, schizophrenia, and depression symptoms; notes approximately 12 ongoing clinical trials